Literature DB >> 22676416

The cancer stem cell subtype determines immune infiltration of glioblastoma.

Christoph P Beier1, Praveen Kumar, Katharina Meyer, Petra Leukel, Valentin Bruttel, Ines Aschenbrenner, Markus J Riemenschneider, Athanassios Fragoulis, Petra Rümmele, Katrin Lamszus, Jörg B Schulz, Joachim Weis, Ulrich Bogdahn, Jörg Wischhusen, Peter Hau, Rainer Spang, Dagmar Beier.   

Abstract

Immune cell infiltration varies widely between different glioblastomas (GBMs). The underlying mechanism, however, remains unknown. Here we show that TGF-beta regulates proliferation, migration, and tumorigenicity of mesenchymal GBM cancer stem cells (CSCs) in vivo and in vitro. In contrast, proneural GBM CSCs resisted TGF-beta due to TGFR2 deficiency. In vivo, a substantially increased infiltration of immune cells was observed in mesenchymal GBMs, while immune infiltrates were rare in proneural GBMs. On a functional level, proneural CSC lines caused a significantly stronger TGF-beta-dependent suppression of NKG2D expression on CD8(+) T and NK cells in vitro providing a mechanistic explanation for the reduced immune infiltration of proneural GBMs. Thus, the molecular subtype of CSCs TGF-beta-dependently contributes to the degree of immune infiltration.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22676416      PMCID: PMC3464079          DOI: 10.1089/scd.2011.0660

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN: 1547-3287            Impact factor:   3.272


  20 in total

1.  TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells.

Authors:  Günter Eisele; Jörg Wischhusen; Michel Mittelbronn; Richard Meyermann; Inja Waldhauer; Alexander Steinle; Michael Weller; Manuel A Friese
Journal:  Brain       Date:  2006-08-03       Impact factor: 13.501

2.  CAMTA1 is a novel tumour suppressor regulated by miR-9/9* in glioblastoma stem cells.

Authors:  Daniel Schraivogel; Lasse Weinmann; Dagmar Beier; Ghazaleh Tabatabai; Alexander Eichner; Jia Yun Zhu; Martina Anton; Michael Sixt; Michael Weller; Christoph P Beier; Gunter Meister
Journal:  EMBO J       Date:  2011-08-19       Impact factor: 11.598

3.  Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines.

Authors:  Jeongwu Lee; Svetlana Kotliarova; Yuri Kotliarov; Aiguo Li; Qin Su; Nicholas M Donin; Sandra Pastorino; Benjamin W Purow; Neil Christopher; Wei Zhang; John K Park; Howard A Fine
Journal:  Cancer Cell       Date:  2006-05       Impact factor: 31.743

4.  SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.

Authors:  Martin Uhl; Steffen Aulwurm; Jörg Wischhusen; Markus Weiler; Jing Ying Ma; Ramona Almirez; Ruban Mangadu; Yu-Wang Liu; Michael Platten; Ulrich Herrlinger; Alison Murphy; Darren H Wong; Wolfgang Wick; Linda S Higgins; Michael Weller
Journal:  Cancer Res       Date:  2004-11-01       Impact factor: 12.701

5.  RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo.

Authors:  Manuel A Friese; Jörg Wischhusen; Wolfgang Wick; Markus Weiler; Günter Eisele; Alexander Steinle; Michael Weller
Journal:  Cancer Res       Date:  2004-10-15       Impact factor: 12.701

6.  Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma.

Authors:  Anastasia Murat; Eugenia Migliavacca; Thierry Gorlia; Wanyu L Lambiv; Tal Shay; Marie-France Hamou; Nicolas de Tribolet; Luca Regli; Wolfgang Wick; Mathilde C M Kouwenhoven; Johannes A Hainfellner; Frank L Heppner; Pierre-Yves Dietrich; Yitzhak Zimmer; J Gregory Cairncross; Robert-Charles Janzer; Eytan Domany; Mauro Delorenzi; Roger Stupp; Monika E Hegi
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

7.  Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis.

Authors:  Heidi S Phillips; Samir Kharbanda; Ruihuan Chen; William F Forrest; Robert H Soriano; Thomas D Wu; Anjan Misra; Janice M Nigro; Howard Colman; Liliana Soroceanu; P Mickey Williams; Zora Modrusan; Burt G Feuerstein; Ken Aldape
Journal:  Cancer Cell       Date:  2006-03       Impact factor: 31.743

8.  CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles.

Authors:  Dagmar Beier; Peter Hau; Martin Proescholdt; Annette Lohmeier; Jörg Wischhusen; Peter J Oefner; Ludwig Aigner; Alexander Brawanski; Ulrich Bogdahn; Christoph P Beier
Journal:  Cancer Res       Date:  2007-05-01       Impact factor: 12.701

9.  Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria.

Authors:  H S Günther; N O Schmidt; H S Phillips; D Kemming; S Kharbanda; R Soriano; Z Modrusan; H Meissner; M Westphal; K Lamszus
Journal:  Oncogene       Date:  2007-11-26       Impact factor: 9.867

10.  Unsupervised analysis of transcriptomic profiles reveals six glioma subtypes.

Authors:  Aiguo Li; Jennifer Walling; Susie Ahn; Yuri Kotliarov; Qin Su; Martha Quezado; J Carl Oberholtzer; John Park; Jean C Zenklusen; Howard A Fine
Journal:  Cancer Res       Date:  2009-02-24       Impact factor: 12.701

View more
  37 in total

1.  SYK inhibition blocks proliferation and migration of glioma cells and modifies the tumor microenvironment.

Authors:  Gerald Moncayo; Michal Grzmil; Tatiana Smirnova; Pawel Zmarz; Roland M Huber; Debby Hynx; Hubertus Kohler; Yuhua Wang; Hans-Rudolf Hotz; Nancy E Hynes; Georg Keller; Stephan Frank; Adrian Merlo; Brian A Hemmings
Journal:  Neuro Oncol       Date:  2018-04-09       Impact factor: 12.300

2.  Metformin inhibits proliferation and migration of glioblastoma cells independently of TGF-β2.

Authors:  Corinna Seliger; Anne-Louise Meyer; Kathrin Renner; Verena Leidgens; Sylvia Moeckel; Birgit Jachnik; Katja Dettmer; Ulrike Tischler; Valeria Gerthofer; Lisa Rauer; Martin Uhl; Martin Proescholdt; Ulrich Bogdahn; Markus J Riemenschneider; Peter J Oefner; Marina Kreutz; Arabel Vollmann-Zwerenz; Peter Hau
Journal:  Cell Cycle       Date:  2016-05-10       Impact factor: 4.534

3.  ICOSLG-mediated regulatory T-cell expansion and IL-10 production promote progression of glioblastoma.

Authors:  Ryoichi Iwata; Joo Hyoung Lee; Mikio Hayashi; Umberto Dianzani; Kohei Ofune; Masato Maruyama; Souichi Oe; Tomoki Ito; Tetsuo Hashiba; Kunikazu Yoshimura; Masahiro Nonaka; Yosuke Nakano; Lyse Norian; Ichiro Nakano; Akio Asai
Journal:  Neuro Oncol       Date:  2020-03-05       Impact factor: 12.300

4.  Activation of the Receptor Tyrosine Kinase AXL Regulates the Immune Microenvironment in Glioblastoma.

Authors:  Hirokazu Sadahiro; Kyung-Don Kang; Justin T Gibson; Mutsuko Minata; Hai Yu; Junfeng Shi; Rishi Chhipa; Zhihong Chen; Songjian Lu; Yannick Simoni; Takuya Furuta; Hemragul Sabit; Suojun Zhang; Soniya Bastola; Shinobu Yamaguchi; Hebaallah Alsheikh; Svetlana Komarova; Jun Wang; Sung-Hak Kim; Dolores Hambardzumyan; Xinghua Lu; Evan W Newell; Biplab DasGupta; Mitsutoshi Nakada; L James Lee; Burt Nabors; Lyse A Norian; Ichiro Nakano
Journal:  Cancer Res       Date:  2018-03-12       Impact factor: 12.701

5.  NKG2D ligands in glioma stem-like cells: expression in situ and in vitro.

Authors:  Charlotte Flüh; Guranda Chitadze; Vivian Adamski; Kirsten Hattermann; Michael Synowitz; Dieter Kabelitz; Janka Held-Feindt
Journal:  Histochem Cell Biol       Date:  2018-01-22       Impact factor: 4.304

Review 6.  The Dynamics of Interactions Among Immune and Glioblastoma Cells.

Authors:  Katalin Eder; Bernadette Kalman
Journal:  Neuromolecular Med       Date:  2015-07-30       Impact factor: 3.843

7.  MNK Inhibition Disrupts Mesenchymal Glioma Stem Cells and Prolongs Survival in a Mouse Model of Glioblastoma.

Authors:  Jonathan B Bell; Frank D Eckerdt; Kristen Alley; Lisa P Magnusson; Hridi Hussain; Yingtao Bi; Ahmet Dirim Arslan; Jessica Clymer; Angel A Alvarez; Stewart Goldman; Shi-Yuan Cheng; Ichiro Nakano; Craig Horbinski; Ramana V Davuluri; C David James; Leonidas C Platanias
Journal:  Mol Cancer Res       Date:  2016-06-30       Impact factor: 5.852

Review 8.  ExRNA in Biofluids as Biomarkers for Brain Tumors.

Authors:  Robert C Rennert; Fred H Hochberg; Bob S Carter
Journal:  Cell Mol Neurobiol       Date:  2016-03-18       Impact factor: 5.046

Review 9.  Targeting tumor metastases: Drug delivery mechanisms and technologies.

Authors:  Vidya Ganapathy; Prabhas V Moghe; Charles M Roth
Journal:  J Control Release       Date:  2015-09-25       Impact factor: 9.776

10.  Impaired TGF-β induced growth inhibition contributes to the increased proliferation rate of neural stem cells harboring mutant p53.

Authors:  Praveen Kumar; Ulrike Naumann; Ludwig Aigner; Joerg Wischhusen; Christoph P Beier; Dagmar Beier
Journal:  Am J Cancer Res       Date:  2015-10-15       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.